Effects of low-dosage simvastatin on rheumatoid arthritis through reduction of Th1/Th2 and CD4/CD8 ratios.
The objective of this study was to assess both the anti-inflammatory and immunomodulatory effects of low-dosage simvastatin on rheumatoid arthritis (RA). In each patient, simvastatin at 10 mg/day was administered for 12 weeks. The other treatments were unchanged at least 3 months before simvastatin administration to the end of the study. Patients were assessed for the improvement in clinical, laboratory, and immunological parameters of RA and for adverse events. Twenty-four patients with RA were enrolled. Clinical symptoms, including patient's assessment of pain and disease activity on visual analog scale (VAS), the swollen joint and tender joint counts, and handgrip strength significantly improved. Physician's assessment of disease activity on VAS, a period of morning stiffness and modified health assessment questionnaire showed a tendency of improving after administration of low-dosage of simvastatin. Of special interest was that the median levels of erythrocytes sedimentation rate, C-reactive protein, and rheumatoid factor were significantly decreased from 54.0 mm/h to 45.5 mm/h, from 1.50 mg/dl to 0.85 mg/dl, and from 57.0 IU/ml to 28.0 IU/ml, respectively, after administration of simvastatin. ACR20 and ACR50 responses were achieved in 62% and 38%, respectively, of simvastatin-treated patients for 12 weeks. Immunological assessment in peripheral blood revealed that the Th1/Th2 and CD4/CD8 ratios were significantly reduced by simvastatin. No adverse events were reported during simvastatin treatment. Immunomodulation through the alteration of Th1/Th2 and CD4/CD8 ratios may be a pharmacological mechanism in the anti-rheumatic effect of low-dosage simvastatin. Although it is necessary to evaluate the long-term effects of statins, low-dosage statins appear to be good as additional therapeutic agents.
Kanda
Hiroko
H
Department of Allergy and Rheumatology, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, and Department of Rheumatology, Sagamihara National Hospital, National Hospital Organization, Kanagawa, Japan. hkanda-tky@umin.ac.jp
Yokota
Kazuhiro
K
Kohno
Chieko
C
Sawada
Tetsuji
T
Sato
Kojiro
K
Yamaguchi
Masao
M
Komagata
Yoshinori
Y
Shimada
Kota
K
Yamamoto
Kazuhiko
K
Mimura
Toshihide
T
D000368:Aged; D000369:Aged, 80 and over; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001799:Blood Sedimentation; D002097:C-Reactive Protein / Q000096:biosynthesis; D015704:CD4 Antigens / Q000096:biosynthesis; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology*; D016827:CD8 Antigens / Q000096:biosynthesis; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D007249:Inflammation; D008297:Male; D008875:Middle Aged; D012217:Rheumatoid Factor / Q000096:biosynthesis; D019821:Simvastatin / Q000008:administration & dosage / Q000627:therapeutic use*; D018417:Th1 Cells / Q000166:cytology*; D018418:Th2 Cells / Q000166:cytology*; D016896:Treatment Outcome
D018501:Antirheumatic Agents; D015704:CD4 Antigens; D016827:CD8 Antigens; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002097:C-Reactive Protein; D012217:Rheumatoid Factor; D019821:Simvastatin